Current Report Filing (8-k)
May 10 2022 - 04:08PM
Edgar (US Regulatory)
false 0001496671 0001496671 2022-05-10
2022-05-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 10, 2022
Calithera Biosciences, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
Delaware |
|
001-36644 |
|
27-2366329 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
343 Oyster Point Blvd. Suite 200
South San Francisco, California
|
|
94080 |
| (Address of principal
executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (650)
870-1000
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
Common Stock, 0.0001 par
value |
|
CALA |
|
The Nasdaq Global Select
Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this
chapter).
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On May 10, 2022, Calithera Biosciences, Inc. (the “Company”)
issued a press release announcing its financial results for the
quarter ended March 31, 2022. A copy of this press release is
attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current
Report on Form 8-K,
including Exhibit 99.1, shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liability of that
section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, whether made before or after the date hereof, except
as expressly set forth by specific reference in such filing to this
Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release, dated May 10,
2022
|
|
|
| 104 |
|
Cover Page Interactive Data File
(the cover page XBRL tags are embedded within the Inline XBRL
document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
Calithera Biosciences, Inc. |
|
|
|
| Dated: May 10, 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Susan M. Molineaux
|
|
|
|
|
|
|
|
|
Susan M. Molineaux |
|
|
|
|
|
|
|
|
President and Chief Executive
Officer |
|
|
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Sep 2023 to Oct 2023
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Oct 2022 to Oct 2023
